An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ...

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based ...

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...